# A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

> **NCT05989724** · PHASE1 · UNKNOWN · sponsor: **Qurgen Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Solid Tumor
- Breast Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** SON-DP

## Key facts

- **NCT ID:** NCT05989724
- **Lead sponsor:** Qurgen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-19
- **Primary completion:** 2025-09
- **Final completion:** 2026-03
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05989724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05989724, "A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05989724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*